NCT05527483View on ClinicalTrials.gov

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

October 10, 2022

Study Completion Date

October 10, 2022

Conditions
Prostate Cancer
Interventions
DRUG

[68Ga]PSMA

Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging

DRUG

Flourine-18 [F-18] Sodium Fluoride (NaF)

Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.

DIAGNOSTIC_TEST

PET/CT

Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT

Trial Locations (1)

44106

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER